Canada's QLT has opted to delay a human trial of an experimental therapy, Atrigel, for people with hormone disorders after reporting adverse events in a primate study. The FDA wants to review data on the primate study before the clinical program gets underway. QLT says it should be able to submit the data by the end of the year. Atrigel is being developed for people whose pituitary glands produce excess growth hormones.
- here's the AP report for more information